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Background ardiovascular diseases are the major cause of mortality in patients with diabetes mellitus (DM) [1] . For adequate prevention of cardiovascular complications, it is necessary to identify their early precursors. One of the markers of cardiovascular diseases is increased arterial stiffness [2, 3] . Pulse wave velocity, a traditionally used parameter for measurement of this marker, has the following limitations: 1) lack of standardization and 2) dependence on the operator and blood pressure (BP) levels. In recent years, a new parameter, cardio-ankle vascular index (CAVI), which does not exhibit any of the aforementioned disadvantages, has been used to assess the arterial stiffness. Studies have demonstrated that CAVI increases in patients with the following risk factors of cardiovascular diseases: 1) hypertension [4] , 2) dyslipidaemia [5] , 3) smoking [6] , 4) low physical activity [7] and 5) DM [8, 9] . A relationship exists between CAVI and the prevalence of both peripheral [10] and coronary [11, 12] atherosclerosis as well as prognostic values in some categories of patients with coronary artery disease [10, 13] . It is impossible to exclude CAVI values in various conditions including impaired glucose metabolism (IGM). Therefore, a relevant reason exists for studying CAVI in diabetic patients, primarily for detection of asymptomatic cardiovascular diseases. The above data were primarily obtained from Asian populations; therefore, it is important to note that regional differences in CAVI values exist in healthy individuals [14] .
Aim
We aimed to examine the factors associated with abnormal CAVI values of patients with type 2 diabetes mellitus (T2DM) and prediabetes in a population-based 'Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of the Russian Federation' (ESSE-RF) study in one of the regions of Western Siberia, Russia.
Materials and methods
This study was conducted within the epidemiological multicenter trial ESSE-RF, wherein CAVI values of patients in the Kemerovo region were specifically investigated. The study population comprised a randomized group of adult males and females (age 25-64 years) from the Kemerovo region. A crosssectional epidemiological trial was performed from March to October, 2013. The preparation of study sample, which involved three phases including serial sampling of municipal medical institutions, medical sites and households, has been mentioned in the study protocol. Of the 2000 people who were asked to participate in this study, 1628 were enrolled (81.4%). Of those enrolled, 1619 fulfilled all study criteria. The study was approved by the Independent Local Ethics Committee of the Research Institute for Complex Issues of Cardiovascular Diseases protocol from meeting No. 61 dated 6 February 2013. Each participant received written informed consent form for study participation. Population examination, according to the cardiac screening program, was conducted during the morning. Physical examination included measurement of BP, heart rate (HR) and anthropometric indicators; a resting 12-lead electrocardiography (ECG) and blood sampling for biochemical laboratory tests. All measurements were performed by staff qualified in cardiac epidemiological research methods.
BP measurements were performed on the right hand of each study participant, adopting a sitting position after a 5 min rest period, using an automatic sphygmomanometer. BP was measured twice with an interval of 2-3 min. The mean value of the two measurements was used for analysis. Arterial Hypertension (AH) was determined as BP of 140/90 mm Hg and higher or BP < 140/90 mm Hg during antihypertensive therapy. Height and weight measurements were performed using a stadiometer with an accuracy of 1 cm and floor electronic medical balance with an accuracy of 100 g. Each examined person removed their shoes and outerwear. Obesity was defined as a body mass index (BMI) ≥ 30 kg/m2, calculated according to the formula: weight in kg/height in m2 (Quetelet index). Waist circumference (WC) and the hip circumference (HC) were also measured for all study participants. Visceral obesity was determined by a WC ≥ 80 cm in women and 94 cm in men [15] . Participants who smoked ≥ one cigarette or more per day were considered to be chronic smokers. IGM was determined according to the diagnostic criteria of DM and other glycaemic disorders [16] .
Blood sampling in examined persons was performed via vein puncture after 12-h fasting. All laboratory procedures were strictly standardized and performed using the same equipment and equipment-specific reagents in clinical laboratories. Glomerular filtration rate (GFR) was calculated on the basis of serum creatinine using the Modification of Diet in Renal Disease Study (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas.
The cardiac screening program included a standard questionnaire comprising the following 12 modules: 1) sociodemographic data of responders; 2) dietary habits; 3) physical activity; 4) smoking; 5) alcohol consumption; 6) health, attitude to health and quality of life ; 7) Standard research protocol ESSE-RF included specific measurements of peripheral arterial stiffness using a VaSeraVS-1000 vascular screening system (Fukuda Denshi, Japan) to obtain automatic CAVI values. The calculation of this parameter was performed using a plethysmogram on four extremities, an ECG and a phonocardiogram using a special algorithm for calculations.
The study design is shown in Figure 1 . From a sample of 1619 people, 318 participants with IGM were isolated on the basis of the following: DM type 1 and 2, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Two patients with type 1 diabetes, 29 patients with values of AnkleBrachial Index (ABI) < 0.9 and 5 patients with unknown CAVI were excluded from the study to avoid a distortion of CAVI values. The final sample, divided into the following two groups, included 282 patients with type 2 diabetes and prediabetes (IFG, IGT): I (n = 41) participants with CAVI ≥ 9.0 (pathological CAVI) and II (n = 241) participants with CAVI < 9.0 (normal CAVI).
Data was analysed using the standard software package StatSoft STATISTICA v.8.0. Distribution of quantitative data was performed using the Shapiro-Wilk test. Because distribution of all quantitative traits varied, they are presented as medians and quartiles (25th and 75th percentile). MannWhitney test and χ2 test were used for comparisons between groups. Fisher exact test with Yates' correction was used for a small number of observations. Logistic regression analysis was performed to assess the association of a binary trait with one or more quantitative or qualitative characteristics. Multivariate regression analysis included variables which have values of the statistical significance test in the univariate analysis was less than 0.1. Previously an identification of possible correlations between the presumed predictors was conducted, and multiple regression models based on identified correlations were constructed. A p value = 0.05 was considered to be significant.
Results
Clinical and anamnestic characteristics of patients are displayed in Table. 1. The majority of patients with IGM in Group I and II were females (73.2% and 65.2%, respectively, p = 0.314). Patients in the group with pathological CAVI were older (p < 0.001) and had a longer history of smoking (p = 0.013).
The majority of patients with IGM in both groups had T2DM (85.4% in Group I and 85.9% in Group II, p = 0.929, Table. 1). T2DM with insulin dependency was significantly more frequent in the group with pathological CAVI (p < 0.001). Patients in both groups displayed the same prevalence of kidney diseases, coronary artery disease and incidence of myocardial infarction.
A larger number of patients in Group I than those in Group II suffered a stroke (12.2% and 2.9% respectively, p = 0.006) and previously had AH (61.0% and 38.2%, respectively, p = 0.006).
Patients in both groups had similar anthropometric parameters (BMI, WC and HP; Table 2 ). High prevalence of obesity (BMI ≥ 30 kg/m2) existed for both groups (51.2 % in Group I and 57.7% in Group II, p = 0.436). Visceral obesity with a WC ≥ 80 cm in women and 94 cm in men was detected significantly more often in individuals with pathological CAVI (95.1% vs. 80.4%, respectively, p = 0.034). Comparison of volumetric sphygmographic parameters (Table 2) shows that systolic blood pressure (SBP) in both groups corresponded to AH parameters, while the median SBP in individuals with pathological CAVI was significantly higher than in those with normal CAVI (157.0 mm Hg and 143.1 mm Hg, respectively; p < 0.001). Median diastolic blood pressure (DBP) was also significantly higher in Group I (94.0 mm Hg and 89.0 mm Hg, respectively, p < 0.001). ABI values were similar for both groups (p = 0.899). CAVI values were higher in Group I (p < 0.001). Median HR was significantly higher in Group I (66.0 and 73.0 bpm in Group I and II, respectively; p < 0.001).
Blood chemistry tests revealed no differences between groups regarding the following lipid profile parameters: glucose and uric acid (p > 0.05, Table 3 ). The median GFR calculated according to CKD-EPI formula was significantly lower in patients with pathological CAVI (p < 0.001), although within the reference range for both groups. The median creatinine and MDRD GFR values were similar for both groups (p > 0.05).
Logistic regression was used for analysis of factors associated with pathological CAVI in the entire sample of patients with IGM (Table 4) . According to univariate analysis, pathological CAVI was associated with increased age, smoking history, prior stroke, hypertension, insulindependent T2DM, visceral obesity, increased HR, SBP and DBP, a decrease in GFR CKD-EPI and MDRD.
According to multivariate analysis age (OR 1.077 per each year of life, 95% CI 1.016-1.142, p = 0.012), SBP (OR 1.024 with increase for every mm Hg, 95% CI 1.006-1.042, p = Table 1   Table 2 Note: data are presented as median [Q25; Q75]. Abbreviations: BMI, body mass index; WC, waist circumference; HC, hip circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CAVI, cardio-ankle vascular index; ABI, ankle-brachial index. Table. 4).
The decrease in GFR CKD-EPI for every 5 ml/min/1.73 m2 was associated with 1.5 times increased likelihood of pathological CAVI (OR 1.506, 95% CI 1.165-1.949, p = 0.002), regardless of gender, visceral obesity and prior stroke. In patients with insulin-dependent T2DM, the likelihood of high CAVI detection was increased more than 10 times (OR 10.238, 95% CI 1.016-98.677, p = 0.031). Adjustment for age were made, regardless of gender, presence of hypertension and smoking history.
Discussion
The present study demonstrates that in a populationbased sample, pathological CAVI values (≥9.0) were present in 14.5% of patients with IGM. Independent factors associated with pathological CAVIs in this cohort of patients were age, increased SBP and HR, decreased GFR and dependence on insulin therapy.
Previous studies have obtained contradictory data concerning a relationship between various factors and pathological CAVI values in patients with diabetes [8, 9, 17, 18, 19] . Perhaps, only the association of CAVI deterioration with increasing age of patients is not divisive among researchers [8, 9, 19] . In the study performed by Tian G. et al. [19] , the only independent predictor of increase in CAVI in patients with DM was patient age, whereas in the other studies, it was noted that CAVI was dependent on the following factors: dyslipidaemia [17] , BP [19] and the degree of IGM control [9, 19] . Shimizu Y. et al. [17] observed increased arterial stiffness (CAVI ≥ 8.0) in diabetic patients with high values of triglycerides/high density lipoproteins ratio (HR 2.57; 95% CI 1.32-5.02), but not in patients with low values of this ratio (HR 1.17; 95% CI 0.52-2.63) [17] . A correlation between CAVI values and total cholesterol (r = 0.101; p < 0.05) was also noted [20] . Unlike data revealed in this study, other studies revealed no association between lipid profiles and CAVIs [9, 19] . Some Spanish authors [19] also observed the same positive correlation between CAVI values and blood pressure as that observed in the present study; however, a correlation was not observed in a Japanese population [9] . A positive correlation between CAVI and BP differences, obtained from measurements on hand, existed in one study involving patients with DM (r = 0.240; p = 0.0005). A multiple linear regression analysis revealing differences in BP, obtained from hand measurement, was an independent determinant of the increase in CAVI (β = 0.213; p = 0.0011) [18] . These data suggest that asymptomatic atherosclerosis existed in these patients; therefore, it is necessary to consider the relationship between CAVI and BMI in DM separately. Other completed studies have not revealed any relationship between CAVI and obesity [9] or any negative correlations between CAVI and body mass index or waist circumference [19] . The univariate logistic regression analysis in the present study revealed a relationship between pathological CAVI and visceral obesity, but not between pathological CAVI and BMI. Apparently, this phenomenon can be explained by the phenotypic obesity differences and BMI increases due to the presence of subcutaneous fat; however, these factors are not necessarily associated with poor cardiovascular prognoses [21] . The presence of visceral obesity, demonstrated by increased WC measurements, is not a not a satisfactory parameter to evaluate metabolism [21, 22] .
A level of IGM control, specific for this group of patients, may indicate a relationship between CAVI values and other clinical and laboratory parameters in patients with DM. Thus, an independent association of CAVI with the postprandial glycaemia [23, 24] and glycated hemoglobin levels (HbA1с) is noted [9, 19] . In addition, the reduction of HbA1с levels due to glycaemic control was significantly correlated with an improvement in CAVI values [9] . Relevant literature has mentioned the influence of various long-term medications on CAVI value decrease [23, 24, 25] .
During 12 months of treatment with acarbose, a decrease occurred both in the postprandial glucose and HbA1c levels as well as some asymptomatic inflammation serum markers (hs-CRP, PTX3, MMP-2 and MMP-9). In addition, there was a significant decrease in CAVI, and the multivariate analysis showed that decreased blood glucose levels, PTX3 expression and MT1-MMP are independent predictors of favourable [23] . Changes in treatment regimens of patients with diabetes may further impact the improvement in vascular stiffness. Thus, 3 months after replacing premixed human insulin (30/70) with biphasic insulin aspart (30/70) a significant decrease in CAVI (from 9.77 ± 1.11 to 9.35 ± 1.17; p < 0.005) was noted, along with a significant negative correlation between change in CAVIs and the concentration of 1,5-anhydro-D-glucitol (1,5-AG), a marker of postprandial hyperglycaemia (r = -0.393; p < 0.05). The reduction of arterial stiffness may also be associated with improved postprandial glucose levels [24] . Comparison of the two groups of patients with DM, including one group receiving glimepiride for 6 months and the other receiving glibenclamide, revealed a significant decrease in CAVI values in only the glimepiride group (from 9.4 ± 1.4 to 8.9 ± 0.8; p < 0.05). The concentration of urine 8-hydroxy-2'-deoxyguanosine (8-OHdG), a marker of oxidative DNA damage, was decreased in the glimepiride group and increased in the glibenclamide group. Changes in the two groups significantly differed (-1.5 ± 3.5 vs +1.8 ± 3.6; p = 0.009). The change in the concentration of 8-OHdG served as a significant independent predictor of the CAVI change among all examined patients. Researchers concluded that the improvement of CAVI values during glimepiride therapy may be mediated by a reduction both in the oxidative stress and insulin resistance [25] .
An important aspect of the CAVI evaluation in patients with DM is its association with the presence of subclinical signs of both peripheral and coronary artery atherosclerosis.
Atherosclerotic plaques in carotid arteries, therefore, were found more frequently in diabetic patients with pathological CAVI than in those with normal CAVIs (89% and 67%, respectively (p < 0.001). In addition, it was observed that a significant correlation between CAVI and the thickness of the intima-media complex exists (r = in 0.288; p < 0.001) [26] . According to the multiple linear regression analysis, an independent positive association between CAVI values and the marker of asymptomatic atherosclerosis mentioned above exists in the European population (β = 0.29; 95% CI 0.09-0.48; p < 0.01 [19] . The presence of pathological CAVI also correlated with the presence of diabetic polyneuropathy (HR 1.36; 95% CI 1.13-1.65; p = 0.001) [26] for target organ lesions in diabetic patients [19] . According to multislice computed tomography (MSCT) of the coronary arteries in asymptomatic patients with IGM, CAVI is also an independent predictor of increased in calcium scores and the severity of coronary artery stenosis [11] . Age, gender, presence of hypertension, diabetes and dyslipidaemia, along with a CAVI of ≥8.0 was associated with severe calcification of the coronary arteries (calcification index of ≥300 Agatston units) and with the presence of significant coronary artery stenosis (OR 3.143; 95% CI 1.004-9.842; p = 0.049) [11] . Additionally, a sample of T2DM patients demonstrated a positive correlation between, CAVI and calcium scores in coronary arteries (r = 0.303, p < 0.0001) [12] .
Clinical significance of CAVI measurements in patients with DM primarily consists of patients demonstrating In addition, the follow-up CAVI evaluation in patients with DM allows assessing the efficacy of therapeutic interventions focused on IGM control (already mentioned) and on pharmaceutical treatment of concomitant pathology [27, 28] . For example, it was shown that a decrease in CAVI, accompanied by a significant reduction of the LDL-CL level occurred in diabetic patients with increased LDL-CL levels after a 6-month treatment regimen of ezetimibe [27] . A significant decrease in CAVI existed for the olmesartan group as opposed to the amlodipine group when treating diabetic patients with hypertension, although the decrease in BP measurements for these groups was comparable [28] . Special studies concerning the effect of risk factors' correction on the CAVI value in patients with DM were not conducted; however, the positive effect of lifestyle modification [29] , physical exercises, weight loss [30] and smoking cessation [6] on this parameter is well-known in other examined cohorts.
Conclusion
In a population-based sample, pathological CAVIs (≥ 9.0) were revealed in 14.5% of patients with IGM. Independent factors associated with abnormal CAVI values in this study cohort were age (OR 1.094; p = 0.003), increase in SBP (OR 1.024; p = 0.007), heart rate (OR 1.027; p = 0.033), reduced CKD-EPI glomerular filtration rate (OR 1.094; p = 0.003) and dependence on insulin therapy (OR 10.238; p = 0.031). Evaluation of CAVI in patients with diabetes is helpful for identifying patients with subclinical manifestations of atherosclerosis, as well as for follow-up efficacy assessment of hypoglycaemic therapy, pharmacological correction of risk factors and for preventive measures. 
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